Please login to the form below

Not currently logged in
Email:
Password:

Defitelio

This page shows the latest Defitelio news and features for those working in and with pharma, biotech and healthcare.

Jazz Pharma bags FDA approval for rare disease drug

Jazz Pharma bags FDA approval for rare disease drug

Jazz acquired Defitelio as part of its $1bn purchase of Italy's Gentium in 2013. ... The company has the opportunity to promote both Erwinaze and Defitelio via its haematology/oncology salesforce, it noted.

Latest news

  • SMC: Celgene's Abraxane 'too expensive' for Scotland SMC: Celgene's Abraxane 'too expensive' for Scotland

    SMC: Celgene's Abraxane 'too expensive' for Scotland. But medicines watchdog backs Sovaldi, Invokana, Defitelio, Relvar Ellipta. ... Drugs that received positive opinions included Janssen's Invokana (canagliflozin) for type 2 diabetes, Jazz

  • Jazz offers $1bn for Italy's Gentium Jazz offers $1bn for Italy's Gentium

    Jazz offers $1bn for Italy's Gentium. Will gain access to recently-approved liver drug Defitelio. ... 10m. Gentium also has a small business unit selling active pharmaceutical ingredients (APIs) which contributed the bulk of the non-Defitelio turnover.

  • Gentium expects EMA rejection for defibrotide Gentium expects EMA rejection for defibrotide

    Negative feedback for drug’s use in liver condition associated with stem cell transplantation

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics